+

WO2002011750A3 - Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway - Google Patents

Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway Download PDF

Info

Publication number
WO2002011750A3
WO2002011750A3 PCT/US2001/041619 US0141619W WO0211750A3 WO 2002011750 A3 WO2002011750 A3 WO 2002011750A3 US 0141619 W US0141619 W US 0141619W WO 0211750 A3 WO0211750 A3 WO 0211750A3
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquitin
blockade
beta
prevention
proteasome
Prior art date
Application number
PCT/US2001/041619
Other languages
French (fr)
Other versions
WO2002011750A2 (en
Inventor
Antonella Favit
Maurizio Grimaldi
Daniel L Alkon
Original Assignee
Us Gov Health & Human Serv
Antonella Favit
Maurizio Grimaldi
Daniel L Alkon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Antonella Favit, Maurizio Grimaldi, Daniel L Alkon filed Critical Us Gov Health & Human Serv
Priority to AU2001281392A priority Critical patent/AU2001281392A1/en
Priority to US10/344,258 priority patent/US20040014678A1/en
Priority to CA002419132A priority patent/CA2419132A1/en
Publication of WO2002011750A2 publication Critical patent/WO2002011750A2/en
Publication of WO2002011750A3 publication Critical patent/WO2002011750A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for inhibiting neurotoxic ubiquitin-proteasome proteolysis, and treatment of neurodegenerative disorders. In particular, a method of suppressing the neurotoxic effect of β-amyloid peptide, by administering an inhibitor to block β-amyloid peptide-mediated ubiquitin-proteasome proteolysis. Preferred inhibitors are inhibitors of ubiquitination, such as leucine-alanine dipeptide, and inhibitors of post-ubiquitination proteasome activity, such as lactacystin.
PCT/US2001/041619 2000-08-08 2001-08-08 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway WO2002011750A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001281392A AU2001281392A1 (en) 2000-08-08 2001-08-08 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
US10/344,258 US20040014678A1 (en) 2001-08-08 2001-08-08 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
CA002419132A CA2419132A1 (en) 2000-08-08 2001-08-08 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22373100P 2000-08-08 2000-08-08
US60/223,731 2000-08-08

Publications (2)

Publication Number Publication Date
WO2002011750A2 WO2002011750A2 (en) 2002-02-14
WO2002011750A3 true WO2002011750A3 (en) 2003-03-13

Family

ID=22837761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041619 WO2002011750A2 (en) 2000-08-08 2001-08-08 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway

Country Status (3)

Country Link
AU (1) AU2001281392A1 (en)
CA (1) CA2419132A1 (en)
WO (1) WO2002011750A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171085A1 (en) * 2002-11-04 2004-09-02 Irm Llc Methods and compositions for treating neurodegenerative diseases
ES2293834B1 (en) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas COMPOSED WITH INHIBITING ACTIVITY OF UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS THERAPEUTIC APPLICATIONS.
GB201212456D0 (en) 2012-07-12 2012-08-29 Univ Sheffield Treatment of muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756764A (en) * 1995-04-12 1998-05-26 President And Fellows Of Harvard College Lactacystin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756764A (en) * 1995-04-12 1998-05-26 President And Fellows Of Harvard College Lactacystin analogs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FAVIT A ET AL: "Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 MAY 12) 95 (10) 5562-7., XP002225660 *
FAVIT A ET AL: "Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway.", JOURNAL OF NEUROCHEMISTRY, (2000 SEP) 75 (3) 1258-63., XP002225661 *
FAVIT, A. (1) ET AL: "Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (2000) VOL. 26, NO. 1-2, PP. ABSTRACT NO.-664.11. PRINT. MEETING INFO.: 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE NEW ORLEANS, LA, USA NOVEMBER 04-09, 2000 SOCIETY FOR NEUROSCIENCE., XP001109221 *
MARAMBAUD P ET AL: "Proteasome inhibitors prevent the degradation of familial Alzheimer 's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells.", MOLECULAR MEDICINE, (1998 MAR) 4 (3) 147-57., XP008011749 *
OBIN M ET AL: "Neurite outgrowth in PC12 cells. Distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 APR 23) 274 (17) 11789-95., XP002225662 *
TABAN C H ET AL: "Effect of a dipeptide inhibiting ubiquitin -mediated protein degradation nerve-dependent limb regeneration in the newt.", EXPERIENTIA, (1996 SEP 15) 52 (9) 865-70., XP001109395 *

Also Published As

Publication number Publication date
AU2001281392A1 (en) 2002-02-18
CA2419132A1 (en) 2002-02-14
WO2002011750A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
NO20006544L (en) C-terminally modified oxamyl dipeptides as inhibitors of the ICE / ced-3 family of cysteine proteases
WO2000055125A3 (en) N-cyanomethyl amides as protease inhibitors
WO2002020475A3 (en) Inhibitors of serine protease activity of matriptase or mtsp1
ZA200200094B (en) Nitrogen containing heterobicycles as factor xa inhibitors.
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2003072528A3 (en) (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
BR0008584A (en) 2-indolyl (n-substituted) c-terminal modified carbonyldipeptides as inhibitors of the ice / c and d-3 family of cysteine proteases
AU1101501A (en) Methods and compositions for treatment of keratoconus using protease inhibitors
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
IL128940A0 (en) C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and pharmaceutical compositions containing them
WO2002057298A3 (en) C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
WO2003099202A3 (en) Beta-secretase inhibitors
MXPA05008240A (en) Cathepsin s inhibitors.
WO2002011750A3 (en) Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
MXPA05008541A (en) Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof.
AU2001252419A1 (en) Thrombin inhibitors
EP1652525A4 (en) Anti-coronavirus drug
NO20073307L (en) Glycine reuptake inhibitors for the treatment of drug and alcohol abuse
AU4650500A (en) Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
WO2005041885A3 (en) Compositions and methods for treating, preventing, reversing and inhibiting pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10344258

Country of ref document: US

Ref document number: 2419132

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载